Home » Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study
Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study
Coherus BioSciences has released positive results from a pharmacokinetic and pharmacodynamic study assessing its biosimilar candidate CHS-1701.
In the biosimilarity study comparing CHS-1701 to Amgen’s Neulasta, the candidate reached all of its co-primary endpoints.
Overall, there were no adverse events related to the treatment.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May